AtriCure (ATRC) | Financial Analysis & Statements
AtriCure Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
140.5M
Gross Profit
105.3M
74.97%
Operating Income
2.5M
1.77%
Net Income
1.8M
1.25%
EPS (Diluted)
$0.04
Balance Sheet Metrics
Total Assets
654.2M
Total Liabilities
162.2M
Shareholders Equity
491.9M
Debt to Equity
0.33
Cash Flow Metrics
Operating Cash Flow
16.3M
Free Cash Flow
17.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
AtriCure Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 534.5M | 465.3M | 399.2M | 330.4M | 274.3M |
| Cost of Goods Sold | 133.7M | 117.8M | 98.9M | 84.4M | 68.5M |
| Gross Profit | 400.8M | 347.5M | 300.4M | 245.9M | 205.9M |
| Gross Margin % | 75.0% | 74.7% | 75.2% | 74.4% | 75.0% |
| Operating Expenses | |||||
| Research & Development | 99.2M | 96.2M | 73.9M | 57.3M | 48.5M |
| Selling, General & Administrative | 311.0M | 291.4M | 253.1M | 231.3M | 204.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 410.2M | 387.5M | 327.1M | 288.6M | 253.2M |
| Operating Income | -9.4M | -40.0M | -26.7M | -42.7M | -47.3M |
| Operating Margin % | -1.8% | -8.6% | -6.7% | -12.9% | -17.2% |
| Non-Operating Items | |||||
| Interest Income | 4.5M | 4.4M | 3.8M | 2.0M | 466.0K |
| Interest Expense | 5.9M | 6.4M | 6.9M | 5.0M | 4.9M |
| Other Non-Operating Income | 683.0K | -1.7M | -31.0K | -537.0K | 102.1M |
| Pre-tax Income | -10.2M | -43.7M | -29.8M | -46.2M | 50.4M |
| Income Tax | 1.3M | 1.0M | 591.0K | 268.0K | 188.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% |
| Net Income | -11.4M | -44.7M | -30.4M | -46.5M | 50.2M |
| Net Margin % | -2.1% | -9.6% | -7.6% | -14.1% | 18.3% |
| Key Metrics | |||||
| EBITDA | 16.2M | -17.2M | -8.1M | -29.5M | -36.8M |
| EPS (Basic) | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.11 |
| EPS (Diluted) | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 |
| Basic Shares Outstanding | 47750000 | 46965000 | 46309000 | 45740000 | 45066000 |
| Diluted Shares Outstanding | 47750000 | 46965000 | 46309000 | 45740000 | 45066000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
AtriCure Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 167.4M | 122.7M | 84.3M | 58.1M | 43.7M |
| Short-term Investments | - | 0 | 53.0M | 63.0M | 75.4M |
| Accounts Receivable | 66.7M | 60.3M | 52.5M | 42.7M | 33.0M |
| Inventory | 78.5M | 75.3M | 67.9M | 45.9M | 39.0M |
| Other Current Assets | 9.9M | 9.4M | 8.6M | 5.5M | 5.0M |
| Total Current Assets | 322.5M | 267.8M | 266.2M | 215.2M | 196.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 34.3M | 31.4M | 27.7M | 25.1M | 24.9M |
| Goodwill | 234.8M | 526.0M | 533.5M | 508.9M | 512.6M |
| Intangible Assets | 48.0M | 56.5M | 64.0M | 39.3M | 43.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 2.9M | 2.9M | 2.2M | 2.0M | 955.0K |
| Total Non-Current Assets | 331.7M | 341.5M | 347.7M | 370.2M | 419.2M |
| Total Assets | 654.2M | 609.3M | 613.9M | 585.4M | 615.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 25.3M | 25.0M | 27.4M | 19.9M | 18.6M |
| Short-term Debt | - | 2.8M | 2.5M | 5.5M | 1.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 3.1M | - | - | 5.5M | 1.8M |
| Total Current Liabilities | 81.5M | 73.4M | 74.6M | 58.4M | 56.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 73.4M | 73.7M | 72.0M | 69.1M | 73.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 7.3M | 1.2M | 1.2M | 1.2M | 1.2M |
| Total Non-Current Liabilities | 80.7M | 74.9M | 73.2M | 70.3M | 75.1M |
| Total Liabilities | 162.2M | 148.4M | 147.8M | 128.7M | 131.6M |
| Equity | |||||
| Common Stock | 50.0K | 49.0K | 48.0K | 47.0K | 46.0K |
| Retained Earnings | -413.2M | -401.8M | -357.1M | -326.6M | -280.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 491.9M | 461.0M | 466.2M | 456.8M | 483.8M |
| Key Metrics | |||||
| Total Debt | 73.4M | 76.5M | 74.5M | 74.5M | 75.6M |
| Working Capital | 241.0M | 194.4M | 191.7M | 156.8M | 139.6M |
Balance Sheet Composition
AtriCure Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -11.4M | -44.7M | -30.4M | -46.5M | 50.2M |
| Depreciation & Amortization | 20.5M | 18.7M | 14.8M | 11.7M | 10.4M |
| Stock-Based Compensation | 44.7M | 40.4M | 35.7M | 28.8M | 28.1M |
| Working Capital Changes | -9.0M | -19.6M | -29.8M | -15.9M | -13.1M |
| Operating Cash Flow | 52.6M | 9.5M | -7.7M | -20.7M | -106.8M |
| Investing Activities | |||||
| Capital Expenditures | -9.0M | -11.4M | -12.0M | -16.9M | -9.8M |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | - | 0 | 0 | -24.6M | -173.1M |
| Investment Sales | 0 | 53.7M | 63.8M | 85.5M | 206.4M |
| Investing Cash Flow | -8.6M | 42.2M | 51.8M | 44.0M | 23.5M |
| Financing Activities | |||||
| Share Repurchases | -11.2M | -7.0M | -6.6M | -12.2M | -18.0M |
| Dividends Paid | 0 | 0 | - | - | - |
| Debt Issuance | 0 | 61.2M | 0 | 0 | 5.0M |
| Debt Repayment | -1.2M | -62.9M | -992.0K | -899.0K | -5.8M |
| Financing Cash Flow | -6.1M | -8.6M | -7.6M | -13.1M | -20.0M |
| Free Cash Flow | 42.3M | -11.3M | -37.5M | -39.0M | -23.5M |
| Net Change in Cash | 37.9M | 43.2M | 36.5M | 10.3M | -103.3M |
Cash Flow Trend
AtriCure Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-117.54
Forward P/E
74.05
Price to Book
2.77
Price to Sales
2.59
PEG Ratio
1.05
Profitability Ratios
Profit Margin
-2.14%
Operating Margin
1.77%
Return on Equity
-2.40%
Return on Assets
-0.94%
Financial Health
Current Ratio
3.96
Debt to Equity
15.54
Beta
1.43
Per Share Data
EPS (TTM)
$-0.24
Book Value per Share
$9.88
Revenue per Share
$11.19
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ATRC | 1.4B | -117.54 | 2.77 | -2.40% | -2.14% | 15.54 |
| Intuitive Surgical | 170.1B | 54.97 | 8.99 | 16.69% | 28.38% | 0.95 |
| Becton, Dickinson | 56.1B | 25.40 | 1.75 | 6.96% | 8.01% | 77.28 |
| Pulse Biosciences | 1.6B | - | 20.17 | -74.45% | -54.00% | 9.34 |
| Staar Surgical | 1.2B | 49.73 | 3.58 | -21.70% | -33.60% | 11.14 |
| Anbio Biotechnology | 1.2B | 181.00 | 39.52 | 27.05% | 74.06% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.






